Roberto Wandenkolk Vieira, the President of Oncology at Corcept Therapeutics Inc, has reported a series of stock transactions in an SEC filing dated November 4, 2026. This filing is significant as it provides insights into the financial activities of a key executive within the company.

Corcept Therapeutics, based in Redwood City, California, operates in the pharmaceutical preparations sector. The company focuses on developing and commercializing therapies for patients with serious metabolic and psychiatric disorders. As of the recent filing, Corcept Therapeutics is listed under the SIC code for pharmaceutical preparations.

The SEC filing reveals that on November 2, 2026, Vieira acquired 8,333 shares of common stock through a stock option, with an exercise price of $21.63 per share. Additionally, he sold a total of 8,333 shares, with the sales occurring at prices ranging from $80.15 to $81.12 per share. Following these transactions, Vieira holds a total of 12,279 shares of common stock directly.

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer," the filing states.

These transactions may have implications for Vieira's financial standing and could influence investor perceptions of Corcept Therapeutics. The filing indicates that Vieira's stock options are set to vest over a period until January 29, 2028, contingent upon his continued service with the company.

As the pharmaceutical industry continues to evolve, the actions of executives like Vieira can provide critical insights into corporate strategies and market positioning. The filing does not specify any upcoming events or further actions related to these transactions.